Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress
- UKPDS 59: Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes. Adler, Amanda I.; Stevens, Richard J.; Stratton, Irene M.; Holman, Rury R.; Neil, Andrew; Boulton, Andrew J. M. // Diabetes Care;May2002, Vol. 25 Issue 5, p894
Presents a study that determined the role of hyperglycemia in prospective analyses of peripheral vascular disease (PVD) in type 2 diabetes taking into account other potential risk factors. Definition of PVD; Potential risk factors for the development of PVD; Comparison between the subjects with...
- Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance. Markolf Hanefeld; Frank Schaper; Carsta Koehler // Cardiovascular Drugs & Therapy;Jun2008, Vol. 22 Issue 3, p225
Abstract IntroductionÂ Â Excessive postprandial (pp) glucose excursion in people with IGT and type 2 diabetes is associated with a cascade of proatherogenic events. Acarbose, a potent competitive inhibitor of Î±-glucosidases of the small intestine specifically reduces pp hyperglycemia with...
- The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Wiernsperger, N.F.; Bailey, C.J. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p31
Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose concentrations in type 2 (non-insulin-dependent) diabetes without causing overt hypoglycaemia. Its clinical efficacy requires the presence of insulin and involves several therapeutic effects. Of these effects,...
- A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus. Howlett, H.C.S.; Bailey, C.J. // Drug Safety;Jun1999, Vol. 20 Issue 6, p489
Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus. Typically it reduces basal and postprandial hyperglycaemia by about 25% in more than 90% of patients when either given alone or coadministered with other therapies...
- Hemodynamic Effects of Acute Hyperglycemia in Type 2 Diabetic Patients. Marfella, Raffaele; Nappo, Francesco; De Angelis, Lorenita; Paolisso, Giuseppe; Tagliamonte, Maria Rosaria; Giugliano, Dario // Diabetes Care;May2000, Vol. 23 Issue 5, p658
Focuses on a study which evaluated the hemodynamic effects of acute hyperglycemia in type 2 diabetic patients and to see whether these effects are related to changes in nitric oxide availability. Research design and methods; Results; Conclusions.
- The Efficacy of Acarbose in the Treatment of Patients with non-Insulin-dependent Diabetes Mellitus. Chiasson, Jean Louis; Josse, Robert G.; Hunt, John A.; Palmason, Carol; Rodger, N. Wilson; Ross, Stuart A.; Ryan, Edmond A.; Tan, Meng H.; Wolever., Thomas M.S. // Annals of Internal Medicine;12/15/94, Vol. 121 Issue 12, p928
Presents a study which evaluated the long-term efficacy of acarbose, an alpha-glucosidase inhibitor, in improving glycemic control in patients with non-insulin-dependent diabetes mellitus. Alternative approach to the problem of postprandial hyperglycemia; Methods used in the study; Results and...
- Morning Hyperglycemic Excursions. Monnier, Louis; Rabasa-Lhoret, Remy; Lapinski, Helene; Caubel, Cecile; Avignon, Antoine; Boniface, Helene; Colette, Claude // Diabetes Care;Apr2002, Vol. 25 Issue 4, p737
Presents a study that determined whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with type 2 diabetes. Protocol of the study and analytical procedures; Comparison of plasma glucose and insulin concentrations...
- Type 2 Diabetes Impairs Splanchnic Uptake of Glucose but Does Not Alter Intestinal Glucose Absorption During Enteral Glucose Feeding. Basu, Ananda; Basu, Rita; Shah, Pankaj; Vella, Adrian; Johnson, C. Michael; Jensen, Michael; Nair, K. Sreekumaran; Schwenk, W. Frederick; Rizza, Robert A. // Diabetes;Jun2001, Vol. 50 Issue 6, p1351
Focuses on the effects of diabetes on the splanchnic uptake of glucose. Decrease in the contribution of extracellular pathway to hepatic glycogen synthesis; Role of abnormal hepatic and muscle glucose metabolism on postprandial hyperglycemia; Characterization of type 2 diabetes.
- Managing hyperglycemia in Type 2 diabetes: Here's how. Fernandez, Julio // Drug Topics;9/18/2006, Vol. 150 Issue 18, p25
The article presents an instructional material on the management of hyperglycemia in patients with non-insulin-dependent diabetes.